| Source HCPCS Code |
|
Target NDC Code |
Q5135
INJECTION, TOCILIZUMAB-AAZG (TYENNE), BIOSIMILAR, 1 MG
|
⇄
|
65219-0584-01
TYENNE AUTOINJECTOR (SD,PF,LATEX-FREE) 162 MG/0.9 ML
|
| Detail Information |
| Relationship Start Date |
10/01/2024 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
0.9 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
|
| Route Of Administration |
SC |
| Billing Units |
ML |
|
|
|
Q5135
INJECTION, TOCILIZUMAB-AAZG (TYENNE), BIOSIMILAR, 1 MG
|
⇄
|
65219-0586-04
TYENNE PFS (SD,PF,LATEX-FREE) 162 MG/0.9 ML
|
| Detail Information |
| Relationship Start Date |
10/01/2024 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
0.9 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
|
| Route Of Administration |
SC |
| Billing Units |
ML |
|
|
|
Q5135
INJECTION, TOCILIZUMAB-AAZG (TYENNE), BIOSIMILAR, 1 MG
|
⇄
|
65219-0590-04
TYENNE (SDV,PF,LATEX-FREE) 20 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
10/01/2024 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
4 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
|
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q5135
INJECTION, TOCILIZUMAB-AAZG (TYENNE), BIOSIMILAR, 1 MG
|
⇄
|
65219-0592-10
TYENNE (SDV,PF,LATEX-FREE) 20 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
10/01/2024 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
10 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
|
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q5135
INJECTION, TOCILIZUMAB-AAZG (TYENNE), BIOSIMILAR, 1 MG
|
⇄
|
65219-0594-20
TYENNE (SDV,PF,LATEX-FREE) 20 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
10/01/2024 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
20 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
|
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q5135
INJECTION, TOCILIZUMAB-AAZG (TYENNE), BIOSIMILAR, 1 MG
|
⇄
|
65219-0596-01
TYENNE AUTOINJECTOR SINGLE DOSE 162 MG/0.9 ML
|
| Detail Information |
| Relationship Start Date |
10/01/2025 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
0.9 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
|
| Route Of Administration |
SC |
| Billing Units |
ML |
|
|
|
Q5135
INJECTION, TOCILIZUMAB-AAZG (TYENNE), BIOSIMILAR, 1 MG
|
⇄
|
65219-0598-10
TYENNE PFS SD 162 MG/0.9 ML
|
| Detail Information |
| Relationship Start Date |
09/29/2025 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
0.9 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
|
| Route Of Administration |
SC |
| Billing Units |
ML |
|
|
|
Q5135
Inj, tyenne, 1 mg
|
⇄
|
65219-0584-01
Tyenne
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q5135
Inj, tyenne, 1 mg
|
⇄
|
65219-0586-04
Tyenne
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q5135
Inj, tyenne, 1 mg
|
⇄
|
65219-0590-04
Tyenne
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q5135
Inj, tyenne, 1 mg
|
⇄
|
65219-0592-10
Tyenne
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q5135
Inj, tyenne, 1 mg
|
⇄
|
65219-0594-20
Tyenne
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|